Brii Biosciences Limited (HKG:2137)

Market Cap	1.50B
Revenue (ttm)	58.52M
Net Income (ttm)	-540.77M
Shares Out	719.18M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,018,000
Average Volume	5,058,925
Open	1.910
Previous Close	1.950
Day's Range	1.890 - 2.120
52-Week Range	0.800 - 3.090
Beta	1.53
RSI	56.01
Earnings Date	May 19, 2025

About Brii Biosciences

Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It develops BRII-296 for th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 98
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2137

Financial Performance

In 2024, Brii Biosciences's revenue was 54.99 million, a decrease of -2.36% compared to the previous year's 56.32 million. Losses were -508.16 million, 190.7% more than in 2023.

Financial numbers in CNY